[1] SMITH D, YONG K. Multiple myeloma [J]. BMJ, 2013, 346(f3863):30-35.
[2] PALUMBO A, ANDERSON K. Multiple myeloma [J]. N Engl J Med, 2011, 364(11): 1046-1060.
[3] KUMAR S K, RAJKUMAR V, KYLE R A, et al. Multiple myeloma [J]. Nat Rev Dis Primers, 2017, 3(17046):1-20.
[4] LANDGREN O, KYLE R A, PFEIFFER R M, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma:A prospective study [J]. Blood, 2009, 113(22): 5412-5417.
[5] EVANS L A, JEVREMOVIC D, NANDAKUMAR B, et al. Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia[J]. Am J Hematol, 2020, 95(6): 637-642.
[6] GHOBRIAL I M. Myeloma as a model for the process of metastasis: implications for therapy [J]. Blood, 2012, 120(1): 20-30.
[7] GINSBERG D M. Circulating plasma cells in multiple myeloma. A method for detection and review of the problem [J]. Ann Intern Med, 1962, 57(5):843-846.
[8] PAIVA B, PAINO T, SAYAGUES J M, et al. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile [J]. Blood, 2013, 122(22): 3591-3598.
[9] KUMAR S, RAJKUMAR S V, KYLE R A, et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance [J]. J Clin Oncol, 2005, 23(24): 5668-5674.
[10] BIANCHI G, KYLE R A, LARSON D R, et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma [J]. Leukemia, 2013, 27(3): 680-685.
[11] GONSALVES W I, RAJKUMAR S V, DISPENZIERI A, et al. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression [J]. Leukemia, 2017, 31(1): 130-135.
[12] SANOJA-FLORES L, FLORES-MONTERO J, GARCÉS J J, et al. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC) [J]. Blood Cancer J, 2018, 8(12): 117-127.
[13] 王晶,耿爽,钟玉萍,等.中华血液学杂志[M].天津:中华血液学杂志编辑委员会,2016,337-339.
[14] DINGLI D, NOWAKOWSKI G S, DISPENZIERI A, et al. Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system [J]. Blood, 2006, 107(8): 3384-3388.
[15] NOWAKOWSKI G S, WITZIG T E, DINGLI D, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma [J]. Blood, 2005, 106(7): 2276-2279.
[16] GONSALVES W I, RAJKUMAR S V, GUPTA V, et al. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma [J]. Leukemia, 2014, 28(10): 2060-2065.
[17] CHAKRABORTY R, MUCHTAR E, KUMAR S K, et al. Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation[J]. Haematologica, 2017, 102(8):1439-1445.
[18] GONSALVES W I, JEVREMOVIC D, NANDAKUMAR B, et al. Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells[J]. Am J Hematol, 2020, 95(3): 310-315.
[19] KUMAR S K, LEE J H, LAHUERTA J J, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study[J]. Leukemia, 2012, 26(1): 149-157.
[20] MIGKOU M, KASTRITIS E, ROUSSOU M, et al. Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy [J]. Eur J Haematol, 2011, 87(4): 323-329.
[21] GONSALVES W I, MORICE W G, RAJKUMAR V, et al. Quantification of clonal circulating plasma cells in relapsed multiple myeloma [J]. Br J Haematol, 2014, 167(4): 500-505.
[22] RAWSTRON A C, OWEN R G, DAVIES F E, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage [J]. Br J Haematol, 1997, 97(1): 46-55.
[23] PECELIUNAS V, JANIULIONIENE A, MATUZEVICIENE R, et al. Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma[J]. Leuk Lymphoma, 2012, 53(4): 641-647.
[24] ABE Y, NARITA K, KOBAYASHI H, et al. Pretreatment (18)F-FDG PET/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma[J]. Eur J Nucl Med Mol Imaging, 2019, 46(6): 1325-1333.[25] WITZIG T E, MEYERS C, THERNEAU T, et al. A prospective study of CD38/45 flow cytometry and immunofluorescence microscopy to detect blood plasma cells in patients with plasma cell proliferative disorders[J]. Leuk Lymphoma, 2000, 38(3/4): 345-350.
[26] AVET-LOISEAU H, LI C, MAGRANGEAS F, et al. Prognostic significance of copy-number alterations in multiple myeloma[J]. J Clin Oncol, 2009, 27(27): 4585-4590.
[27] FLORES-MONTERO J, SANOJA-FLORES L, PAIVA B, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma[J]. Leukemia, 2017, 31(10): 2094-2103.
[28] KORTHALS M, SEHNKE N, KRONENWETT R, et al. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma[J]. Biol Blood Marrow Transplant, 2013, 19(7): 1109-1115.
[29] YAO Q, BAI Y, ORFAO A, et al. Upgraded standardized minimal residual disease detection by next-generation sequencing in multiple myeloma[J]. J Mol Diagn, 2020, 22(5): 679-684. |
